IONS — Ionis Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $7.33bn
- $7.19bn
- $943.71m
U.S. STOCKS ON THE MOVE-Oracle, Vanda, Keysight
Ionis drops after forecasting 2026 revenue below expectations
Ionis Pharma Q4 revenue beats expectations, helped by TRYNGOLZA EU launch
Brief: Dawnzera™ (Donidalorsen) Approved In The European Union For Hereditary Angioedema (Hae)
Brief: Biogen Says Co Received European Commission Approval For High Dose Regimen Of SPINRAZA
U.S. STOCKS ON THE MOVE-Nvidia, Boeing, Lowe's
Ionis hits seven-year high after partner GSK reveals promising hepatitis B trial results
Brief: Ionis Receives U.S. FDA Breakthrough Therapy Designation For Olezarsen For Severe Hypertriglyceridemia
US FDA approves Arrowhead's genetic disorder drug (updated)
US FDA approves Arrowhead's genetic disorder drug
Brief: Biogen Completes Acquisition Of Alcyone Therapeutics
Brief: DAWNZERA Receives Positive Opinion From CHMP, Recommended For Approval In EU For Hereditary Angioedema
U.S. STOCKS ON THE MOVE-Broadwind, Verizon, APA
U.S. STOCKS ON THE MOVE-Firefly Aerospace, Salarius, Spectrum Brands
Ionis Pharma dips after $700 mln convertible bonds sale
Brief: Ionis Prices $700 Million Aggregate Principal Amount Of 0.00% Convertible Senior Notes Due 2030
Ionis Pharma up after unveiling $700 mln convertible bonds offering
Brief: Ionis Announces Proposed Convertible Offering To Refinance 2026 Convertible Notes
U.S. RESEARCH ROUNDUP-Doordash, Honeywell, Zscaler